Latest ImmunityBio News & Updates

See the latest news and media coverage for ImmunityBio. We track all announcements, press releases, and industry mentions in real time, all in one place.

ImmunityBio

Biotechnology company developing immunotherapies for cancer and infectious diseases

immunitybio.com

Headquarters: San Diego, United States
Founded year: 2014
Company type: Public company
Number of employees: 600–1,000

Last updated Today

Latest news about ImmunityBio

In short: ImmunityBio reached record Q1 2026 revenue of $44.2 million and received FDA acceptance for a supplemental BLA to expand ANKTIVA's label.

Company announcements

May 20 ImmunityBio

ImmunityBio announces FDA acceptance of sBLA for ANKTIVA plus BCG

The sBLA seeks to expand ANKTIVA's label to BCG-unresponsive NMIBC with papillary disease, with a PDUFA date of January 6, 2027.

May 19 ImmunityBio

ImmunityBio presents comparative effectiveness data for NAI+BCG at AUA 2026

The data show higher complete response rates and longer duration compared to nadofaragene and TAR-200, with fewer adverse events.

May 18 ImmunityBio

ImmunityBio announces U.S. patents for ANKTIVA plus BCG through 2035

The five patents cover methods, compositions, and kits for treating non-muscle invasive bladder cancer, reinforcing the company's commercial position.

May 16 ImmunityBio

ImmunityBio signs exclusive U.S. agreement for Tokyo strain BCG

The agreement provides a second potential BCG source to address the U.S. shortage.

Media coverage

Yesterday Morningstar

...Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class...

ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against...

May 20 Investing.com

FDA accepts ImmunityBio’s application for Anktiva expansion By Investing.com

FDA accepts ImmunityBio’s application for Anktiva expansion...

May 20 Yahoo Finance

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License...

May 19 The Globe and Mail

ImmunityBio Secures Exclusive Tokyo-172 BCG Rights in U.S.

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.

Never miss news about ImmunityBio

Track ImmunityBio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

ImmunityBio competitors & trending companies

Browse news for competitors to ImmunityBio and other trending companies.